Skip to main content

School of Pharmaceutical Sciences, Universiti Sains Malaysia

  • Qualification

    PhD (Pharmacometrics) (The Uni. of Queensland, Australia), MPharm (Clinical Pharmacy), BPharm (Hons)

  • Associate Professor

    Discipline of Clinical Pharmacy

  • Coordinator

    PRP Academia@USM

  • Vice Secretary

    PAGMAS

  • Room

    J01 Room 134

  • Contact

    +604-6577888 Ext. 4587

  • Email

    sabariahnoor@usm.my

Author ID

Sabariah Noor Harun, Assoc Prof Dr

Dr Sabariah, a pharmacometrician, senior lecturer, and registered pharmacist at the School of Pharmaceutical Sciences, USM, obtained her PhD from the pharmacometric group at The University of Queensland, Australia. Her research encompasses time to event, disease progression and drug effect modelling, pharmacokinetics/pharmacodynamics, and simulation studies, particularly in diseases with high variability in response, such as non-communicable diseases, e.g. diabetes, stroke and infectious diseases. Dr Sabariah established a pharmacometric research cluster group called S&S PRC@USM. This research cluster was developed together with Dr Siti Maisharah. Further information on the S&S PRC@USM can be found here: https://rb.gy/59qvzt.

Dr Sabariah plays a pivotal role in supervising g a diverse group of students, including PhD, MSc, MPharm (Clinical Pharmacy), and final-year project students. She is highly regarded as a speaker and tutor for national and international pharmacometrics seminars. Notably, she has served as the Vice Treasury of the Population Approach Group of Malaysia (PAGMAS), a society dedicated to pharmacometrics research, since February 2021, following her tenure as Vice Secretary from February 2018 to January 2021. More details about my research and publications can be found here: https://experts.usm.my/cvitae/sabariahnoor  

  1. Pharmacometrics
    1. Concepts, methodology and application of population pharmacokinetic and pharmacodynamic modelling and simulation approach
    2. Time to event modelling
    3. Disease progression modelling
  2. Clinical pharmacy – Infectious disease, Stroke, Diabetes
  3. AI/machine learning in Pharmacy Education

Ongoing Research

  1. An insight into the relationship between blood clearance and volume distribution of insulin and glucose on the blood coagulation and inflammatory biomarkers during acute ischemic stroke.
  2. Development of Population PK models of first-line antituberculosis
  3. Development of Population PKPD model of Vancomycin in non-ICU patient
  4. Development of a predictive model of recurrent ischemic stroke in the Malaysian population
  5. An insight on the relationship between rifampicin concentration and glucose level on the tuberculosis treatment outcomes among patient with co-existing type 2 diabetes mellitus and tuberculosis
  6. Optimisation of Rivaroxaban Therapy in Non-valvular Atrial Fibrillation Patients with Heart Failure using Population Pharmacokinetic/Pharmacodynamic Modelling: An Integration of Pharmacometrics Model
  7. Pharmacometric Time-to-event and Disease Progression Modelling of Diabetic Nephropathy in Patients with Type II Diabetes Mellitus
  1. Pharmacometrics modelling & simulation 
    1. Population pharmacokinetic and pharmacodynamic model development
    2. Disease progression model development
    3. Time-to-event model development
  2. Clinical pharmacy research
  1. Elhefnawy ME, Ghadzi SMS, Noor Harun S. Predictors Associated with Type 2 Diabetes Mellitus Complications over Time: A Literature Review. Journal of Vascular Diseases. 2022;1(1):13-23.
  2. Mohd Rahimi Muda* , Sabariah Noor Harun, Syed Azhar Syed Sulaiman, Siti Maisharah Sheikh Ghadzi *, 2022, Population Pharmacokinetics Analyses of Rifampicin in Adult and Children Populations: A Systematic Review, British Journal of Clinical Pharmacology, 2022:, 1-21 (Impact Factor : 4.34, DOI :HTTPS://DOI.ORG/10.1111/BCP.15298)
  3. Orwa Albitar* , Sabariah Noor Harun, Rama Ballouze , Dzul Azri Mohamed Noor , Siti Maisharah Sheikh Ghadzi*, 2022, A time-dissociated pharmacokinetics pharmacodynamics model of cyclosporine among Malaysian renal transplant recipients., Therapeutic Drug Monitoring, 44:, (Impact Factor : 3.681, DOI :10.1097/FTD.0000000000000916)
  4. Harun SN, Holford NHG, Grimwood K, Wainwright CE, Hennig S. Pseudomonas aeruginosa eradication therapy and risk of acquiring Aspergillus in young children with cystic fibrosis. Thorax. 2019;74(8):740-8.
  5. Harun SN, Wainwright CE, Grimwood K on behalf of the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study group, et al Aspergillus and progression of lung disease in children with cystic fibrosis Thorax 2019;74:125-131.
  6. Harun, S. N., Wainwright, C., Klein, K., & Hennig, S. (2016). A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. Paediatric respiratory reviews, 20, 55-66.
  7. Albitar, O., Harun, S. N., Ahmad, S. N. A., & Sheikh Ghadzi, S. M. (2021). A Repeated Time-to-Positive Symptoms Improvement among Malaysian Patients with Schizophrenia Spectrum Disorders Treated with Clozapine. Pharmaceutics, 13(8), 1121.
  8. Chow NK, Harun SN, Wong EJ, Low LL, Sheikh Ghadzi SM, Khan AH. The association between cigarette smoking and efavirenz plasma concentration using the population pharmacokinetic approach. Br J Clin Pharmacol. 2021;(November 2020):1–10.
  9. Chow NK, Khan AH, Harun SN. Association between cigarette smoking and plasma concentration of efavirenz: A systematic review. HIV AIDS Rev. 2021;20(1):10–6.
  10. Rehman A, Shah S, Abbas G, Harun SN, Shakeel S, Hussain R, et al. Assessment of risk factors responsible for rapid deterioration of lung function over a period of one year in patients with chronic obstructive pulmonary disease. Sci Rep [Internet]. 2021;1–11. Available from: https://doi.org/10.1038/s41598-021-92968-5
  11. Albitar O, Ballouze R, Harun SN, Mohamed Noor DA, Sheikh Ghadzi SM. Population Pharmacokinetic Modeling of Cyclosporine Among Malaysian Renal Transplant Patients: An Evaluation of Methods to Handle Missing Doses in Conventional Drug-Monitoring Data. J Cl
  1. FAR 241 Antimicrobial
  2. FAR 454 Applied Therapeutics II
  3. FCP 551 Pharmacotherapeutics I
  4. FCP 552 Pharmacotherapeutics II
  5. FCP 553 Pharmacotherapeutics III
  6. FCP 560 Medical 2 Internship
  7. Clinial Pharmacy II (Undergraduate clerkship)
  8. HFF 224
  9. MTAC Clerkship
  1. Population pharmacokinetic and pharmacodynamic models’ development for drug development, post-marketing drug & repurposing drug
  2. Pharmacometrics modelling consultation
  3. Clinical pharmacy research
  4. Clinical pharmacy
  1. silver Award. Pitching (Educator) at The Virtual International e-Content Development Competition 2023, Ministry of Higher Education (International)
  2. Gold Medal. SimPCare@USM: An innovative Online Simulated Clinical Pharmacy Clerkship Platform, Ministry of Higher Education, International University Carnival on E-Learning (IUCEL) 2022, 2022 (International )
  3. Gold Award for the Pitching (Educator), Ministry of Higher Education, The Virtual International e-Content Development Competition 2021, 2021 (International)
  4. 1st Runner up of the MSC 2022 Best Oral Presentation Award, Malaysia Stroke Conference 2022
  5. Anugerah Khas USM, Petugas Operasi Pusat Pemberian Vaksin (PPV) Universiti Sains Malaysia
  6. Pemenang Anugerah Sanggar Sanjung 2019
  7. Anugerah Perkhidmatan Cemerlang 2019
  8. The Best Publication in Pharmacometrics 2016, The University of Queensland, Australia
  1. Fundamental Research Grant Scheme Grant, 2020, Ministry of Higher Education, Malaysia, RM 152,200.00
  2. Fundamental Research Grant Scheme Grant, 2019, Ministry of Higher Education, Malaysia RM 176,800.00
  3. Short Term Grant, 2019, Universiti Sains Malaysia, RM 30,184.69
  4. Bridging Grant, 2020-2021, Universiti Sains Malaysia, RM 25,000.00
  5. Incentive Grant, 2012, Universiti Sains Malaysia| RM 5000.00